evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 2 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 50%High 3 · 50%

Chemotherapy alone vs same chemotherapy plus radiotherapy

Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages)

Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).

1 finding from 1 review

Dose‐intensified chemotherapy vs ABVD‐like chemotherapy (with or without radiotherapy

Progression/relapse · Patients with untreated Hodgkin lymphoma (advanced stages)

Dose‐intensified chemotherapy probably leads to lower progression/relapse compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).

1 finding from 1 review

Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation

Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)

Chemotherapy plus lower‐dose radiation showed no clear difference in progression/relapse compared with same chemotherapy plus higher‐dose radiation (high certainty).

1 finding from 1 review

Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation

Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)

Chemotherapy plus involved‐field radiation showed no clear difference in progression/relapse compared with same chemotherapy plus extended‐field radiation (high certainty).

1 finding from 1 review

Fewer vs more courses of chemotherapy (with or without radiotherapy

Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)

Fewer showed no clear difference in progression/relapse compared with more courses of chemotherapy (with or without radiotherapy (high certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Progression/relapse · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate probably leads to lower progression/relapse (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review